The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Clonal evolution – an important factor in treating CLL
Philip Thompson, MD, from The University of Texas MD Anderson Center, Houston, TX explains the importance of detecting subclonal genetic mutations such as TP53 in patients with chronic lymphocytic leukemia (CLL), noting that often, the mutant cells in these patients become resistant to chemotherapy and therefore survive, which results in patients undergoing relapse. As there are now drugs that act in a TP53-dependent manner, such as ibrutinib and venetoclax, he states that detection of these mutations is vital towards targeting CLL patients for effective therapy. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
